Teranochem develops non-toxic, small molecule-based anticancer drugs that target mitochondria to minimize side effects in patients. The company focuses on creating first-in-class therapies for intractable diseases, including cancer, aging, and neurodegenerative disorders, through advanced drug synthesis techniques.
Funding
Funding not disclosed
Founders
Product
Problem
Current anticancer drugs often cause significant side effects due to their lack of specificity, damaging healthy cells along with cancerous ones. This can severely impact patients' quality of life and limit the effectiveness of treatment.
Solution
Teranochem is developing a new class of small molecule-based anticancer drugs that selectively target mitochondria within cancer cells. By focusing on mitochondria, the company aims to disrupt cancer cell metabolism and induce apoptosis while minimizing harm to healthy tissues. Their approach leverages advanced drug synthesis techniques to create first-in-class therapies for intractable diseases. Teranochem's pipeline includes treatments for cancer, aging, and neurodegenerative disorders, all designed to be patient-friendly with reduced side effects.
Target Audience
The primary target audience includes patients with cancer, aging-related diseases, and neurodegenerative disorders, as well as the healthcare providers who treat them.
Features
- Antibiotic-based next-generation anticancer drugs that target mitochondria.
- Low-molecular-weight anti-aging therapeutics that selectively remove senescent cells.
- Low-molecular-weight therapeutics for neurodegenerative diseases that alleviate the neurotoxicity of pathogenic proteins.